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Heart failure is a complex syndrome of numerous dysfunctional components which converge to cause chronic progressive failure of ventricular
contractile function and maintenance of cardiac output demand. The aim of this brief review is to highlight some of the mounting evidence
indicating that augmented superoxide, related reactive oxygen species and other free radicals contribute to the oxidative stress evident during the
progression of heart failure. While much of the source of increased reactive oxygen species is mitochondrial, there are other intracellular sources,
which together are highly reactive with functional and structural cellular lipids and proteins. Bioenergetic defects limiting ATP synthesis in the
failing myocardium relate not only to post-translational modification of electron transport respiratory chain proteins but also to perturbation of
Krebs Cycle enzyme-dependent synthesis of NADH. Accumulation of pathological levels of lipid peroxides relate to dysfunction in the intrinsic
capacity to clear and renew dysfunctional proteins. This review also features key limitations of human heart failure studies and potential clinical
therapies that target the elevated oxidative stress that is a hallmark of human heart failure.
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Heart failure, a syndrome resulting in the chronic and pro-
gressive loss of ventricular systolic function, is one of the lead-
ing causes of death worldwide [1]. Despite significant advances
in the treatment of heart failure, morbidity and mortality from
heart failure remain high, with the overall one-year mortality
estimated at 20–30% for mild to moderate failure and over 50%
for severe heart failure. Heart failure may be categorised ac-
cording to differing underlying etiology, including ischemic
heart disease (coronary artery disease, myocardial infarction),
cardiomyopathy (dilated, hypertrophic), valvular disease, alco-
hol/drug-induced heart disease and hypertensive heart disease.
In economically advanced nations, ischemic heart disease ac-
counts for almost 75% of heart failure cases [1].
Central to the loss of contractile function in heart failure is
the inability of mitochondria to adequately supply the myo-
cardium with ATP, resulting in energy deprivation to the cell⁎ Corresponding author. Tel.: +61 385321310; fax: +61 385321314.
E-mail address: spepe@baker.edu.au (S. Pepe).
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doi:10.1016/j.bbabio.2006.03.008and potentially necrotic/apoptotic cell death. It has been ap-
proximated that most mitochondrial ATP-derived energy
supports myocardial contraction and the maintenance of ion
homeostasis, 75% and 25% of cardiomyocyte energy consump-
tion, respectively [2]. However, the underlying molecular causal
events leading to metabolic dysfunction are poorly understood.
The production of reactive oxygen species (ROS) has been
shown to increase in the failing heart, and due to their close
proximity to sites of superoxide production, mitochondrial pro-
teins and lipids may be targets of oxidative damage in the failing
heart. In this brief review, we describe the evidence linking
increased mitochondrial ROS production in the failing myocar-
dium and the potential for oxidative modification of mitochon-
drial proteins leading to dysfunction in ATP synthesis, and thus
highlight potential targets for therapy.
2. Energy metabolism in heart failure: Krebs cycle versus
respiratory chain
The heart is the greatest oxygen-consuming organ in the
body, consuming around 8–15 ml O2 min/100 g human heart
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conditions. [2]. Of this, 90% of available oxygen is consumed
by mitochondria, which occupy over 30% of cardiomyocyte
volume. Both fatty acid and carbohydrate metabolism converge
at the Krebs cycle, with the generation of reduced redox carriers
NADH and FADH2 providing substrate for mitochondrial ATP
synthesis. The Krebs cycle provides a major point of regulation
of energy metabolism at three key enzymes, citrate synthase
(CS), isocitrate dehydrogenase (ICDH) and α-ketoglutarate
dehydrogenase (α-KGDH) due to their highly negative ΔG°′
values (standard free energy of ATP hydrolysis) [3]. Notably,
the latter two of these three enzymes, along with pyruvate
dehydrogenase, are linked to complex I via their supply of
NADH, and thus serve NADH oxidation and the regulation of
energy flow through the electron transport chain protein com-
plexes, resulting in the reduction of oxygen to water. The proton
motive force generated by this process drives ATP synthesis via
the F1Fo–ATP synthase complex (complex V) [3].
Reduced ATP synthesis, as measured by a lowering of state
III (ADP-coupled) respiration has been demonstrated in isolated
cardiac mitochondria from failing animal [4] and human [5]
hearts, relative to non-failing controls. In an attempt to identify
possible causes for this decline, many studies have focused on
the measurement of the electron transport chain enzymes in a
number of human cardiomyopathies. Most notably, complex I
[6], complex III [7], and complex IV [8] have been identified as
dysfunctional in end-stage human heart failure. A direct causal
relationship, however, has proven elusive over the years, with a
poor correlation between reduced complex activities and the
severity of disease [7]. This may be partly explained by a large
reserve capacity for activity of each respiratory protein com-
plex. For example, up to 50% inhibition of complex I or IV
activity is required before a significant decline in state III res-
piration is apparent [9].
In contrast, Krebs cycle enzymes involved in the regulation
of substrate metabolism appear to exert more direct control over
energy output, with a close correlation between the loss of α-
KGDH activity and decreased state III respiration [13]. Due to
their close interaction with complex I, a major site of
mitochondrial superoxide formation, NADH-linked enzymes
such as α-KGDH and ICDH may be susceptible to ROS-
dependent perturbation. Reduced ICDH activity (∼30%) has
been demonstrated as an early marker of hypertrophy before the
onset of ventricular dysfunction, in transgenic hypertrophic car-
diomyopathic mice [10] and spontaneously hypertensive rats
(SHR), [11]. The decline in α-KGDH, PDH and ICDH activity
coincides with the formation of protein thiol adducts with 4-
hydroxy-2-nonenal (HNE), a lipid peroxidation aldehyde formed
via reaction between arachidonic acid and superoxide [12–16].
Reduced α-KGDH activity together with increased HNE-adduct
formation has also been described in aged rats [9]. However, the
specific role that perturbation of these enzymes may play in
contributing to an energy deficit in the failing heart awaits detailed
examination. Nevertheless it is apparent that diminished
mitochondrial energy metabolism in the failing heart involves
dysfunction in Krebs cycle regulation, NADH supply and activity
of electron transport chain proteins.3. Heart failure is a state of augmented oxidative stress
There is a large body of evidence that markers of oxidative
stress are augmented in the plasma and tissue of patients with
heart failure [17,18]. Due to the short half-life of oxygen free
radicals, most studies have relied on the measurement of lipid
oxidation products. However, these products (such as mal-
ondialdehyde, MDA) are often removed from the source and
magnitude of the initial oxidative reaction, as they are inter-
mediates that may undergo further conversion or reaction with
proteins, and thus offer limited diagnostic marker specificity.
Despite this, the convenience of assay simplicity, low cost and
general association with oxidation rate has sustained their con-
tinued use. Elevated MDA concentration has been measured in
the plasma of patients with moderate symptoms of congestive
heart failure (NYHA III, left ventricular ejection fractions less
than 40%), compared to age-matched non-failing controls
(ejection fractions greater than 40%), which increased with the
duration (years) of congestive heart failure [17]. A significantly
high concentration of plasma MDA and reduced thiol has also
been reported in heart failure patients with underlying coronary
artery disease [19]. Mak and coworkers [20] demonstrated that
total aldehydes are elevated in the plasma of heart failure
patients, with a strong negative correlation between total alde-
hydes and contractility (+dP/dt) as well as increased time to
relaxation (−dP/dt). Keith et al. [18] also reported a correlation
between severity of heart failure and elevated lipid peroxides
and MDA in both ischemic heart disease and dilated car-
diomyopathy patients with end-stage heart failure. Another in-
direct marker of oxidative stress, 8-iso-prostaglandin F2α,
derived from the oxidation of arachidonic acid, is increased in
the pericardial fluid of patients in proportion to the severity of
heart failure of ischemic and/or valvular disease origin [21].
Direct evidence of augmented myocardial superoxide pro-
duction in the failing heart has been established in studies using
electroparamagnetic spin resonance (EPR) spectroscopy (“spin-
trapping”). Increased superoxide production has been demon-
strated in the myocardium of explanted human heart failure
tissue compared to non-failing donor heart muscle [22], con-
firming the results obtained in a pacing-induced animal model
of heart failure [23]. However, in vivo, real time demonstration
of increased cardiac superoxide metabolism in human heart
failure is yet to be determined. It is also crucial to determine
whether there are differences in superoxide metabolism ac-
cording to the etiology, responsible cell type (smooth muscle,
fibroblast, endothelial cell or cardiomyocyte) and progression
of human heart failure.
4. Sources of oxygen radicals in the failing myocardium
A significant contribution of oxygen radical generation in the
cardiomyocyte originates within mitochondria during oxidative
phosphorylation. It is estimated that 1–2% of oxygen is in-
completely converted to H2O during electron transfer, resulting
in the formation of ROS such as the superoxide (–O2
−) and
hydroxyl (OH−) anions and hydrogen peroxide (H2O2) [24].
The reactivity of oxygen derives from its incomplete pairing of
545F.L. Sheeran, S. Pepe / Biochimica et Biophysica Acta 1757 (2006) 543–552electrons in the outer electron shell, and thus single electron
transfer forms the superoxide anion, –O2
− [3]. The proposed sites
of mitochondrial superoxide formation are at complex I (NADH
dehydrogenase) [25], and the ubisemiquinone site of complex III
[26], as demonstrated using targeted inhibitors. Due to the
location of sites of oxygen radical formation, complex I is ex-
pected to release superoxide towards the mitochondrial matrix,
whereas superoxide generated at complex III may be directed
towards both the matrix and intermembrane space [26,27].
Through the use of mass spectroscopy, protein subunits pro-
truding into themitochondrial matrix have been shown to bemost
at risk from oxidative damage as targets of HNE binding, or
carbonyl and nitrosyl modification under basal conditions [28].
Increased superoxide formation by complex I has been directly
measured in the sub-mitochondrial fraction from failing cardio-
myocytes, together with a significant loss of complex I activity
[23], implicating the mitochondrial electron transport chain as a
significant contributor to the pathogenesis of heart failure.
It has been proposed that the amount of superoxide formed is
increased under state IV as opposed to state III respiration, due
to lower ADP availability and increased molecular oxygen,
whereas uncoupling conditions lower the production of ROS.
Basal respiration has been shown to increase in patients with
congestive heart failure [30] by increased resting oxygen con-
sumption, indicating an underlying increase in basal ROS
production in the diseased state. Under conditions of inefficient
mitochondrial respiration due to reduced complex I activity,
ROS production may also be increased [31,32].
5. Endogenous antioxidant systems and ROS management
Mitochondria possess a number of endogenous antioxidant
systems which normally metabolise ROS under physiological
conditions. These include enzymes such as manganese super-
oxide dismutase (MnSOD), glutathione peroxidase and cata-
lase, as well as non-enzymatic components such as coenzyme
Q10, glutathione, α-lipoic acid and vitamin E. Although it is
beyond the scope of this review to specifically cover each of
these, it is important to note that under normal conditions they
constitute a complex network of redox-signal transduction and
ROS management essential to the containment of ROS-me-
diated damage but in heart failure their capacity is breached.
MnSOD, which is exclusively mitochondrial, accounts for 70%
of total heart SOD activity and 90% of that within the myocyte.
MnSOD converts superoxide to hydrogen peroxide, which in
turn is converted to water by catalase and glutathione per-
oxidase, which uses reduced glutathione as an electron donor.
However, under certain circumstances, H2O2 may react with
free iron or copper to produce the highly aggressive OH− radical
[31]. The crucial nature of MnSOD was illustrated experimen-
tally when MnSOD expression was inhibited in a mouse
knockout model. Early death was prevalent for these mice as a
result of dilated cardiomyopathy that occurred with a con-
comitant rise in ROS production [29]. Whether antioxidant
status directly contributes to the development or severity of
heart failure remains under debate. However, in diseased tissue
where increased mitochondrial superoxide production togetherwith reduced antioxidant capacity may exist, the possibility of
overproduction of oxygen free radicals and hence damage to
mitochondrial components may therefore increase. The impact
of this effect on cardiac cells is exacerbated when ROS pro-
duction at non-mitochondrial sites is also augmented.
6. Non-mitochondrial sources of ROS in the failing heart
ROS are also produced in the heart through several other
cellular processes. These include the enzymatic xanthine–xan-
thine oxidase system and NAD(P)H oxidase, activation of
inflammatory pathways by infiltrating granulocytes (neutro-
phils and monocytes), cytochrome P450, the oxidation of cate-
cholamines, as well as the uncoupling of nitric oxide (NO)
synthase (NOS) [3,17,33]. Under certain conditions, NO may
also pair with superoxide to form highly reactive peroxynitrite,
however the source of NO may also be mitochondrial [34–37].
In human and animal models of heart failure, xanthine oxidase
expression is markedly augmented [38–40]. A recent study ex-
amining a canine model of pacing-induced heart failure [41]
showed that treatment of failing hearts with allopurinol or as-
corbic acid resulted in increased contractility and improved me-
chanical efficiency on the basis of increased work performed per
unit of oxygen. However, this amelioration of mechanical work-
oxygen utilisation efficiency could be prevented with the NOS
inhibitor, NG-monomethyl-L-arginine. In non-failing control
hearts, similar NOS inhibition resulted in diminished mechanical
efficiency that could be reversed by allopurinol or ascorbic acid.
Together these data indicate a close interaction between the xan-
thine oxidase and NOS systems over their regulation of oxygen
metabolism and myocardial contractile function and which also
underlie mechano-energetic uncoupling in the failing heart.
The primary function of NAD(P)H oxidases appears to be
ROS production via the electron transfer of NADPH to molec-
ular oxygen [42]. While there are 5 isoforms of NAD(P)H
oxidases, each encoded by separate genes, these have varied
expression according to cell type, with isoforms 2 and 4 being
most abundantly expressed in endothelial cells, fibroblasts and
myocytes [42]. Heymes and coworkers [43], reported in a recent
study that myocardial NAD(P)H oxidase activity and related
ROS formation was increased in end-stage heart failure patients
and was related predominantly to altered translocation of the p47
regulatory subunit of NAD(P)H oxidase. Pathophysiological
features common in the development of cardiac hypertrophy and
heart failure that have been shown to also trigger activation of
NAD(P)H oxidases include, Angiotensin II [44], endothelin 1
[45], α-adrenergic receptor activation [46], TNF-α, P38 MAPK
[33,37,47–49], and stretch [50]. Secondary consequences of
NAD(P)H oxidase-derived ROS may involve subsequent
promotion of further ROS formation, in particular this includes
the activation of xanthine oxidase [51], and the oxidation of the
essential NOS cofactor tetrahydrobiopterin that results in the
uncoupling of NOS [52]. Such consequences may be intrinsic to
facilitating redox-sensitive intracellular signal transduction
involved in the adaptive remodelling mechanisms that included
fibroblast and vascular smooth muscle cell proliferation,
myocyte hypertrophy, fibrosis and alteration of extracellular
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failure [53–56]. However the specific pathways and extent of
signalling pertaining directly to NAD(P)H oxidase activation
are yet to be fully delineated.
7. The impact of ROS on NO regulation of mitochondrial
function
As described above, ROS-induced oxidation of tetrahydro-
biopterin results in the uncoupling of NOS [52], thus abrogating
the physiological regulatory role of NOS over mitochondrial
function and subsequently yielding to the increased expression
of NOS isoforms involved in pathological sequelae. NO is
formed via NOS from the substrates arginine, oxygen and
NADPH and obligatorily requiring tetrahydrobiopterin and
calmodulin [57]. Although there are three NOS isoforms de-
pendent on separate genes; endothelial NOS, neuronal NOS,
and inducible NOS [58], mitochondrial NOS has also been
reported [59–61]. However it remains unclear as to whether
mitochondrial NOS is derived from one of the three reported
NOS isoforms, particularly as NO easily and rapidly diffuses in
water and through membranes. NOS isoforms are heteroge-
neously distributed not only in the numerous cell types of the
heart but also across subcellular compartments, for example, in
myocytes NOS isoforms are expressed in the sarcolemma,
sarcoplasmic reticulum, and mitochondria [61–63]. Under
physiological conditions, NO nitrosylates the haem moiety of
soluble guanylyl cyclase to activate the formation of 3′,5′-cyclic
guanosine monophosphate and subsequently activate protein
kinase G in a complex cascade of signal transduction underlying
numerous regulatory events [64]. NO from endothelial NOS
plays a crucial cardiac role in coronary vasodilation, chrono-
tropy, atrioventricular node function, inotropy, neutrophil and
platelet regulation, it also regulates mitochondrial oxygen con-
sumption [65–69]. At nanomolar concentrations NO also
regulates mitochondrial respiration by reversibly competing
with oxygen for the cytochrome c oxidase (complex IV) oxygen
binding site on a beat-to-beat, cyclic basis, and despite reducing
oxygen consumption, actually improves mechanical efficiency
(stroke work relative to oxygen utilisation) and permits oxygen
consumption to efficiently meet fluctuations in oxygen supply
[41,61,70–72].
Poderoso et al. [73] demonstrated in isolated rat mitochon-
dria that inhibition of the respiratory chain by physiological
levels of NO enhances superoxide formation which reacts with
NO to form peroxynitrite anion and thus in doing so permits
reversal of NO-induced inhibition and resumption of cyto-
chrome c oxidase activity. Under these physiological conditions
intramitochondrial peroxynitrite levels are low and extremely
short lived (b1 s half-life) and only when peroxynitrite is
elevated to high micromolar concentrations that succinate de-
hydrogenase is inhibited and H2O2 formation augmented [74].
Thus, it has been proposed that this NO-dependent reversible
inhibition of cytochrome c oxidase is a mechanism that facil-
itates oxygen diffusion further along its gradient attenuating the
steepness of the PO2 gradient across to more distant mito-
chondria and cells [73].In contrast, inducible NOS increases NO to supra-physio-
logical levels (μM) in response to inflammatory cytokines,
shear stress and other conditions often linked to, but not ex-
clusive to, cardiac pathology [75]. Peroxynitrite and related
reactive nitrite species, formed when NO reacts with superox-
ide, promote inhibition of mitochondrial respiratory proteins
and other proximal proteins such as catalase, aconitase, super-
oxide dismutase and creatine kinase via lipid peroxidation and
protein thiol nitrosylation [70,76–78]. Under physiological con-
ditions, glutathione-dependent formaldehyde dehydrogenase
has been identified in its capacity to degrade sulphide–NO
bonds, however this has not been well characterised in the heart
[79,80]. It is yet to be determined whether there are the specific
changes in the expression or function of this enzyme system
during the development of heart failure.
Notably NO plays an important role in anti- and pro-apoptotic
signal transduction. While low nanomolar amounts of NO keep
the mitochondrial permeability transition pore closed, high mic-
romolar levels promote pore opening and cytochrome c release
eventually triggering apoptosis when sustained [81,82]. In
chronic heart failure, NO and TNFα production are markedly
augmented in proportion to severity of failure [83]. NO has been
demonstrated to increase Bax protein expression and initiate
caspase activation facilitating apoptosis [84,85]. In post-infarct
models of heart failure, apoptosis contributes to poor cell sur-
vival of myocytes in the remote myocardium and in cardiac
allograft rejection [86–91]. Thus, in heart failure, increased NO
and superoxide formation, increased NO inhibition of respira-
tion, increased peroxynitrite and reactive nitrite species for-
mation, increased lipid peroxidation and thiol/protein adduct
formation ultimately lead to the inactivation of numerous
mitochondrial proteins. With mitochondrial function greatly
compromised, subsequent energy dissipation and contractile
dysfunction contribute further to the spiralling progression of
cellular injury and heart failure.
8. Indirect markers of ROS-dependent cell damage
The superoxide anion is relatively short-lived and imperme-
able to the mitochondrial inner membrane, making its direct
measurement difficult. Experimental measures have therefore
relied on the use of secondary markers of ROS formation.
Unsaturated membrane fatty acids are a particular target of
oxygen radical attack due to their unsaturated bonds, resulting
in the formation of lipid peroxidation products. Aldehydic pro-
ducts of high biological abundance are malondialdehyde
(MDA, saturated) and 4-hydroxy-nonenal (HNE, unsaturated).
HNE is formed by the interaction between membrane omega-6
polyunsaturated fatty acids and superoxide, producing a re-
latively stable, highly unsaturated aldehydic compound. Com-
pared to the limited action of ROS, the stability of aldehydes
such as HNE readily permits diffusion from the site of initial
ROS generation and produce protein perturbation distant from
their origin, thus propagating and amplifying the oxidative
injury. Due to its unsaturated bonds, HNE readily attacks amino
acid residues, primarily cysteine, lysine and histidine residues
through Michael-type reactions and has been shown to cause
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gene transcription and is generally a potent ‘toxic’ second mes-
senger pervading numerous other intracellular targets [12,92].
HNE has been show to be elevated in the plasma of heart failure
patients [20], and has been demonstrated as a potent inhibitor of
mitochondrial NADH-linked state III respiration in isolated rat
heart mitochondria at pathological concentrations [13–15].
Aldehydes, including HNE, are detoxified and cleared via the
aldose reductase pathway [93], recently identified as an
important component of the heart's intrinsic capacity to manage
lipid peroxidation-derived aldehydic products under physiolog-
ical conditions. It has thus been hypothesised that the accu-
mulation of lipid peroxides in plasma and myocardium of heart
failure patients may, at least in part, be related to dysfunction of
the aldose reductase pathway. Srivastava and colleagues [93],
recently found support for this proposal using a chronic canine
model of left ventricular-pacing induced heart failure. In early
and late stages of heart failure, oxidative stress indices increased
while cardiac aldose reductase expression and activity decreased
progressively during the progression of heart failure. In early
heart failure translational and/or post-translational modification
of aldose reductase occurs, whereas in the late stages of heart
failure there is a reduced transcriptional regulation and ex-
pression of aldose reductase [93]. However, the direct measures,
specific role and the mechanisms of HNE contribution to
mitochondrial dysfunction in human heart failure have yet to be
examined.
9. ROS damage to mitochondria
Increased oxidative stress in the failing myocardium is asso-
ciated with global cellular defects, including impaired contrac-
tility and electrical instability [19]. Cellular targets of oxidative
attack include the sarcoplasmic reticulum Ca2+ pump, resulting
in reduced Ca2+efflux, ultimately increasing likelihood for Ca2+-
overload [94]. HNE impairment of other ion handling proteins
such as the Na+/ K+ATPases [95,96] and Ca2+–Mg2+ATPases
[97] has been demonstrated in vitro.
Exposure to free radicals in the intact ventricles of rabbits
and guinea pigs has been shown to cause rapid increase in K+
efflux, as well as progressive shortening of the action potential,
with a 50% reduction in tissue high-energy phosphates (ATP
and CP) [98]. In isolated patch-clamped myocytes, free-radical
generation (xanthine–xanthine oxidase) resulted in irreversible
inhibition of glycolytic and mitochondrial oxidative metabo-
lism, matched to that induced by FCCP and the glycolytic
inhibitor 2-DOG [98].
Much of the work involving oxygen radical damage to
mitochondria has focused on ischemia–reperfusion injury. Fol-
lowing an acute ischemic insult and reperfusion of the hypoxic
myocardium, a burst of ROS is seen within the first few minutes
[99,100], resulting from recommencement of mitochondrial
oxidative phosphorylation. Due to the low ADP levels in
ischemic tissue, when oxidative phosphorylation recommences,
lack of ADPmeans that electron transfer is impaired, resulting in
a build up of incomplete oxygen molecules. Of particular
susceptibility to mitochondrial oxidative damage are membrane-bound proteins, lipids and DNA in close proximity to the sites of
superoxide formation, namely the electron transport chain com-
plexes I, III and IV, unsaturated membrane phospholipids and
mitochondrial DNA (mtDNA). As discussed in the sections
above, the reaction of superoxide with NO initiates the formation
of peroxynitrite and related reactive nitrite species which also
inhibit the activity of numerous mitochondrial proteins and
accentuate lipid peroxidation and further ROS formation
[70,76–78]. It is, however, important to now draw our attention
to the impact of oxidative damage on cardiolipin because the loss
of cardiolipin has marked consequences on mitochondrial func-
tion [101,102].
Cardiolipin, due to its highly unsaturated fatty acid chains, is
particularly susceptible to oxidative attack [103–105]. Due to
its close interaction with sites of ROS formation (complexes I
and III) it is a strong target of oxidative attack in the reperfused
myocardium. Paradies and associates have reported 25% and
50% reductions in activities of complexes I and III following
ischemia and ischemia–reperfusion, with significant increases
in mitochondrial MDA levels [103,104]. Complex IV, which
requires a tight association with cardiolipin for optimal function
was also reduced to the same extent following IR, despite con-
stant amounts of heme aa3 being present in control and ischemic
groups [105]. Reperfusion also resulted in a significant decrease
in mitochondrial membrane cardiolipin content.
Cardiolipin has been recognized as being an essential factor for
the correct assembly and function of electron transport chain
complexes and other components of the inner mitochondrial
membrane and is required for their optimal function [106]. In-
terestingly, cardiolipin treatment of mitochondria isolated from
hearts subjected to ischemia–reperfusion restored electron
transport complex activities to almost control levels, thus dem-
onstrating a major role of cardiolipin in the overall function of the
mitochondrion [107].
In addition to complexes I, III and IV, the adenine translocase
has been demonstrated as having an absolute requirement for
cardiolipin and is highly susceptible to ROS [107]. Notably,
perturbation or loss of cardiolipin is a key contributing factor to
mitochondrial release of cytochrome c and apoptosis [106,108].
Although there is some evidence of diminished cardiolipin
levels in heart failure from animal models [109,110], no pub-
lished studies to date have directly measured cardiolipin levels
in the failing human heart.
Unlike nuclear DNA, mitochondrial DNA is more suscep-
tible to oxidative attack, lacking introns, histones and other
DNA-associated proteins involved in protection or faster rates
of DNA repair. Under basal conditions, mitochondrial DNA
displays increased oxidative damage to guanosine bases com-
pared to nuclear DNA, indicating the likelihood of accumulated
mtDNA damage leading to disease is therefore higher [111]. In
a post-myocardial infarcted murine model of heart failure, in-
creased superoxide production coinciding with decreased
mtDNA copy number has been demonstrated. Gene expression
of the electron transport chain subunits encoded on the mito-
chondrial genome, whose transcription is governed by the
mtDNA copy number, was also reduced, reflected by reductions
in activity of complexes I, III and IV [112]. However, in end-
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in both ischemic and dilated cardiomyopathic human explant
tissues, no alteration in gene expression has been detected in
any of the mitochondrial-encoded electron transport chain sub-
unit genes [6,7]. This suggests that disruption of enzymes
involved in mitochondrial energy metabolism may occur at the
post-translational level.
10. Antioxidant and other therapy in heart failure
The issue of whether antioxidant therapy is an effective
treatment for congestive heart failure remains in heated debate.
Coenzyme Q10, which is an essential component of electron
transfer as well as a potent antioxidant in all cell membranes,
has been the subject of numerous human trials. While many
received positive results in improvements in contractility and
blood pressure following treatment, most showed no overall
difference in patient mortality, within the limitations of study
design. Coenzyme Q10 treatment outcome effects in human
trials have been mixed [113–115].
Improvements in terms of reduced oxidative stress (TBARS)
have also been reported with administration of vitamin E, and
this was associated with improved cardiac contractility [116]. In
addition, a 20% reduction in mortality at 20 weeks was seen in
the vitamin E-treated heart failure rats compared to sham con-
trols, as well as reduced clinical heart failure symptoms
(dyspnea, abdominal enlargement, limb cyanosis). However
the use of vitamin E is controversial in humans and is associated
with negative outcome studies and numerous concerns [117].
New considerations of the use of omega-3 polyunsaturated
fatty acids in heart failure are presently being tested clinically
[118]. The impetus for this therapeutic strategy is the mounting
evidence of the pervasive beneficial impact of omega-3 poly-Fig. 1. Scheme of factors influencing mitochondrial ROS production in the failing m
death.unsaturated fatty acids on mitochondrial biogenesis, nuclear
receptor-dependent changes in transcription, intrinsic antioxidant
enzyme expression, eicosanoid and cytokine signalling, mem-
brane and cytosolic/matrix protein function (ion channels, pumps,
enzymes) and efficiency in oxygen consumption [119–122].
One problem faced by even the most potent of agents, is that
once the pattern of cell loss and cardiac remodelling is in place,
late commencement of therapeutic treatment may only limit
further damage, and advanced progression to severe end-stage
failure may prevent the myocardium to survive and sustain
function. New therapies must not only treat hemodynamic dys-
function and symptoms associated with heart failure, but also
slow the initiation of cell loss and oxidative damage [123].
Agents such as Levosimendan have been proven to be promising
in both the short-term treatment and long-term survival of pa-
tients with acute heart failure. Levosimendan enhances contrac-
tion by increasing myofilament sensitivity to calcium [124,125].
In addition, Levosimendan alters cardiac metabolism by its
potent vascular smooth muscle vasodilation via activation of
KATP channels in the plasma membrane, and by also acting
directly at mitochondrial KATP channels (see review by Papp
[126]). Maytin and coworkers [123], have demonstrated that
incubation of isolated rabbit left ventricular myocytes in culture
with levosimendan reduces hydrogen peroxide-induced apopto-
sis to approximately half that of control (hydrogen peroxide
only), which could be blocked by the KATP channel blocker 5-
HD. In addition to improving hemodynamic function, it also
results in a significant improvement in long-term survival [127].
Other drugs also exert antioxidant or free radical scavenging
effects in addition to their effects on vasodilation and beta-
adrenergic receptor blockade. Hydralazine, a very old vasodi-
lator drug, has in recent times been used successfully to improve
cardiac output, reduce cardiac filling pressures, improve ejectionyocardium and the effects of oxygen radical damage on cellular dysfunction and
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patients with congestive heart failure [128]. In particular, hydra-
lazine is able to limit nitrate tolerance that blunts the anti-
ischemic effects of glyceryltrinitrate and is a potent scavenger of
free radicals that limits peroxynitrite formation [36]. While
nicorandil beneficially opens both KATP channels and donates
nitric oxide, it also limits superoxide-dependent formation of
urinary 8-epi-prostaglandin-F2α in patients with acute myocar-
dial infarction [129]. Carvedilol was used initially for its beta-
adrenergic receptor blockade action. Most notably, carvedilol
treatment of patients with dilated cardiomyopathy for 9 months,
not only resulted in amelioration of heart failure symptoms but
also reduced HNE-protein adduct immuno-reactivity in ventric-
ular tissue biopsies by 40% [130]. Despite encouraging promise
from many potential therapeutic agents, considerable effort is
still required to convincingly demonstrate efficacy in human
heart failure at clinical trial level. The complexity of the multiple
defects, adaptations, diverse etiology and rates of progression
that occur in human heart failure, coupled with the expense and
difficulty of executing clinical trials, is a major hurdle to
overcome before new therapeutic agents are routinely employed
successfully.
11. Limitations of human studies and conclusion
The study of oxidative stress-induced mitochondrial damage
in human heart diseased tissue has been problematic. One of the
main problems faced is obtaining true controls. Normal (non-
failing) tissue is often collected up to 6 h post-mortem, being
subjected to brain death and ischemic stress up to this point. In
some cases ‘control tissue’ may in fact contain more oxidative
damage than the failing group. Many of these mitochondrial
defects in particular are also subject to age-dependent dif-
ferences. ROS production is known to increase with age, as
does reduced antioxidant capacity. These factors need to be
taken into account before final analyses. Unlike most animal
heart failure models, human tissue studies are also complicated
by prior heart failure treatments. As most published biochemical
studies have relied on explanted severe end-stage failing hearts,
the data acquired in these studies may not necessarily be extra-
polated back to patients that are in earlier, more moderate stages
of heart failure. As discussed above some drugs currently used
in heart failure also have antioxidant properties, and many
patients today self-treat with non-pharmaceutical agents such as
coenzyme Q10 and vitamin E. Consumption of these may be
masking true ROS levels. Finally, most of the sampling of ROS
has involved downstream markers such as lipid peroxidation
products, and often sampling has been only in plasma, thus not
reflecting tissue-specific ROS metabolism.
Despite these limitations, there is certainly evidence that
oxidative stress is increased in the failing myocardium and that
amongst many factors, key mitochondrial proteins (respiratory
chain and Krebs Cycle) at close proximity to the sites of ROS
generation are subsequently perturbed, limiting or ceasing func-
tion. (See Fig. 1 for a general scheme summary). Whether
oxidation-induced damage plays a significant role in dysfunc-
tion in mitochondrial oxidative phosphorylation in human heartfailure warrants further investigation. New agents and clinical
trials are required to determine whether specific treatments that
directly target the efficiency of oxygen metabolism, NADH and
ATP synthesis, ROS formation and handling, and the clearance
of lipid and protein adducts from cell membranes, plasma and
myocyte contractile components, may prove valuable in
attenuating the progression of heart failure.
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